Supemtek TIVr

Profile

⁺This study used Supemtek (quadrivalent recombinant influenza vaccine), the efficacy of which is relevant to Supemtek TIVr because both vaccines are manufactured using the same process and have overlapping compositions.¹ rVE in 8,604 adults aged ≥50 years, randomised 1:1 to receive a single dose of Supemtek TIVr or SD-IIVe during the A/H3N2-dominant 2014/15 influenza season³

^*Recommended for 27/28 flu season

JCVI discussion on UKHSA Vaccine Effectiveness Data

Adults aged 18-64 in clinical risk groups

JCVI minutes on UKHSA data stated that in 2025-2026 IIVr showed a significantly higher effectiveness against influenza A-related hospitalisation compared to IIVc.⁴

A combined analysis of UKHSA data across four influenza seasons from 2022 to 2026 [IIVr data from 22/23, 23/24,25/26] demonstrated that IIVr showed a significant relative vaccine effectiveness of 23% (aIIV showed a relative vaccine effectiveness of 14%) against influenza A hospitalisations compared with IIVc^4**

Adults aged 65+

JCVI minutes on UKHSA data stated the same analysis showed a significant relative vaccine effectiveness of 19% against influenza A hospitalisations compared with aIIV in adults aged 65+^4**.

** This was a UKHSA analysis looking at the last 4 UK influenza seasons using a test negative case-control design. This uses a reference vaccine to calculate relative vaccine effectiveness.⁵

Real world data

JCVI would like to see more use of Supemtek TIVr alongside all preferred influenza vaccines to improve estimates of vaccine effectiveness^2~

UKHSA vaccine effectiveness data, published by Whitaker HJ et al. in Influenza and Other Respiratory Viruses, indicated a 40% and 24% absolute effectiveness against hospitalisation for Supemtek TIVr for the 2022/23 and 2023/24 seasons respectively (absolute effectiveness of aIIV was 24% & 17% respectively) for those aged 65 and over.^4,8*

~ JCVI advised that all preferred vaccines (aIIV, aIIVc, IIVc, IIV-HD, IIVr) should be used in the UK programme to enable rigorous evaluation. 
* Confidence intervals overlapped and the difference in point estimates was not statistically significant. 
The efficacy of Supemtek (quadrivalent recombinant influenza vaccine) is relevant to Supemtek TIVr because both vaccines are manufactured using the same process and have overlapping compositions

Clinical Evidence

A joint first-line recommended flu vaccine with head-to-head RCT efficacy data against another flu vaccine

Supemtek has shown proven efficacy against another flu vaccine in a head-to-head RCT study, the gold standard of clinical research^1,3

Types of study design

A phase 3-4 randomised controlled trial of 8,604 patients ≥50 years of age was conducted during the A/H3N2-dominant 2014/15 influenza season, and patients were randomised 1:1 to receive a single dose of Supemtek or SD-QIVe. Result based on attack rate of influenza-like illness confirmed by RT-PCR. This study found that Supemtek showed 30% greater relative risk reduction (1% absolute risk reduction) against influenza-like illness versus standard-dose QIVe.

Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older

Usage

With one vaccine for adults for all ages, Supemtek TIVr has the potential to simplify your flu vaccination campaign²

Supemtek TIVr is joint first-line JCVI recommended across all reimbursable adult cohorts.²

Table of JCVI recommended flu vaccines

Efluelda TIV-HD▼ Trivalent Influenza Vaccine (split virion, inactivated) High Dose, 60mcg HA/strain Prescribing Information

Note: A large amount of data on pregnant women (more than 14 500 pregnancy outcomes from a retrospective study), indicates no malformative nor foeto/neonatal toxicity of Quadrivalent Influenza Vaccine (recombinant, prepared in cell culture) (Supemtek) when administered during pregnancy. One animal study performed with Supemtek TIVr did not indicate direct or indirect harmful effects with respect to pregnancy, embryo-foetal development or early post-natal development. Supemtek TIVr can be used during pregnancy in accordance with official recommendations.²

* Equally suitable options.

Recombinant technology

Supemtek is the first recombinant influenza vaccine in Europe.

Recombinant technology eliminates the possibility of adaptation or mutation by replicating only the haemagglutinin (HA) antigen direct from a genetic sequence. The resulting antigens are an exact genetic match to the target strain HA antigen.^5.6

Increased HA content

Supemtek contains 3x more HA antigen (45 mcg versus 15 mcg) per strain, compared with cell and egg-based standard-dose quadrivalent influenza vaccines.¹

Adverse Events

Supemtek TIVr offers the reassurance of a known immunogenicity and safety profile^1,3

Safety data for Supemtek TIVr are derived from the quadrivalent recombinant influenza vaccine as both vaccines are manufactured using the same process and have overlapping compositions.^1,3 The most common reactions that occurred after Supemtek administration were injection-site reactions: tenderness was reported by 48%, and pain by 37%, in study participants 18–49 years of age. In study participants ≥50 years of age, injection site tenderness was reported by 34% and injection site pain by 19%.^1,3 The severity of the adverse reactions was mild to moderate. Onset usually occurred within the first 3 days after vaccination. All resolved without sequelae.¹ Immunogenicity and safety of Supemtek was assessed in children aged 9-17 years. Results showed an immunogenicity non-inferior to the one in 18-49 years old and no additional safety concerns were identified.^1,7 For the full list of adverse events please refer to the Summary of Product Characteristics.

Other adverse events included:¹

Read more about Influenza:

.